Details for Patent: 6,221,339
✉ Email this page to a colleague
| Title: | Medicaments |
| Abstract: | A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament. |
| Inventor(s): | Akehurst; Rachel Ann (Ware, GB), Taylor; Anthony James (Ware, GB), Wyatt; David Andrew (Ware, GB) |
| Assignee: | Glaxo Group Limited (Middlesex, GB) |
| Filing Date: | May 10, 1999 |
| Application Number: | 09/307,552 |
| Claims: | 1. A pharmaceutical aerosol formulation consisting essentially of (i) a particulate medicament which is triamcinolone acetonide, (ii) 1,1,1,2-tetrafluoroethane as propellant, and (iii) 0.05 to 5% w/w based upon propellant of a polar cosolvent which is ethanol, the particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament. 2. A pharmaceutical aerosol formulation consisting of (i) a particulate medicament which is triamcinolone acetonide, (ii) 1,1,1,2-tetrafluoroethane as propellant, and (iii) 0.05 to 5% w/w based upon propellant of a polar cosolvent which is ethanol, the particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size less than 100 microns. 3. A formulation as claimed in claim 1 wherein the polar cosolvent is present in an amount of 0.05 to 3% w/w based upon the propellant. 4. A formulation as claimed in claim 1 wherein the polar cosolvent is present in an amount of less than 1% w/w based upon the propellant. 5. A formulation as claimed in claim 1 wherein the polar cosolvent is present in an amount of approximately 0.1% w/w based upon the propellant. 6. A formulation as claimed in claim 1 wherein the particulate medicament is present in an amount from 0.01% to 1% w/w relative to the total weight of the formulation. 7. A formulation as claimed in claim 2 wherein the polar cosolvent is present in an amount of 0.05 to 3% w/w based upon the propellant. 8. A formulation as claimed in claim 2 wherein the polar cosolvent is present in an amount of less than 1% w/w based upon the propellant. 9. A formulation as claimed in claim 2 wherein the polar cosolvent is present in an amount of approximately 0.1% w/w based upon the propellant. 10. A formulation as claimed in claim 2 wherein the particulate medicament is present in an amount from 0.01% to 1% w/w relative to the total weight of the formulation. 11. A pharmaceutical aerosol formulation consisting essentially of (i) particulate medicament which is triamcinolone acetonide, (ii) 1,1,1,2-tetrafluoroethane as propellant, and (iii) approximately 0.1% w/w based upon propellant of a polar cosolvent which is ethanol, the particulate medicament being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament. 12. A pharmaceutical aerosol formulation consisting of (i) particulate medicament which is triamcinolone acetonide, (ii) 1,1,1,2-tetrafluoroethane as propellant, and (iii) approximately 0.1% w/w based upon propellant of a polar cosolvent which is ethanol, the particulate medicament being present in an amount from 0.01 to 1% w/w relative to the total weight of the formulation and having a particle size less than 100 microns. 13. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as claimed in claim 1. 14. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as claimed in claim 2. 15. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as claimed in claim 11. 16. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as claimed in claim 12. |
